High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Status Active, not recruiting

Clinical Trial Summary

This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body. Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor and may be a better treatment in patients with prostate cancer.

Clinical Trial Description

PRIMARY OBJECTIVES: To estimate the rate of acute (within 6 months of high-dose rate [HDR] completion) grade ≥ 2 genitourinary (GU) toxicity following high-dose-rate (HDR) brachytherapy (BT) as monotherapy for newly-diagnosed prostate cancer using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3 (CTCAE v3.0). SECONDARY OBJECTIVES: - Estimate the proportion of men with a prostate-specific antigen (PSA) nadir by one year (nPSA12) of < 2 ng/mL. - Estimate the rate of freedom from biochemical failure at 5 years (FFBF). - Evaluate patient-reported quality of life via the 32-item Expanded Prostate Cancer Index Composite (EPIC). - Assess the cost-effectiveness of HDR BT as monotherapy for prostate cancer using the 6-item European Quality of Life 5-Dimensions (EQ-5D). - Explore pre-treatment clinical risk factors to optimize patient selection for HDR BT as monotherapy for prostate cancer. - Compare acute and late (> 6 months after HDR completion) GU and gastrointestinal (GI) grade ≥ 2 toxicity using CTCAE v3.0 and v4.0. - Explore dosimetric predictors of toxicity. Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients may receive androgen deprivation therapy (ADT) comprising bicalutamide orally (PO) once daily (QD). Patients may also receive luteinizing hormone-releasing hormone (LHRH) agonist therapy comprising leuprolide acetate intramuscularly (IM) or subcutaneously (SC), goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4 to 6 months (intermediate-risk patients receiving ADT) or 6 to 36 months (high-risk patients) at the discretion of the treating physician. After completion of study treatment, patients are followed up at 3, 6, 9, and 12 months, and then yearly for up to 5 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02346253
Study type	Interventional
Source	Stanford University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 13, 2015
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03796767` - Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer	Phase 2
Completed	`NCT04400656` - PROState Pathway Embedded Comparative Trial
Completed	`NCT05735223` - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence	N/A
Recruiting	`NCT04175431` - Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study	Phase 2
Completed	`NCT05197257` - 68Ga-PSMA-11 PET in Patients With Prostate Cancer	Phase 3
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Terminated	`NCT02491411` - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel	N/A
Active, not recruiting	`NCT02254746` - A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer	N/A
Active, not recruiting	`NCT05496959` - 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study	Phase 2
Completed	`NCT02940262` - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy	Phase 3
Recruiting	`NCT04391556` - Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma	Phase 2
Enrolling by invitation	`NCT03503643` - Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Recruiting	`NCT05832086` - Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes	Phase 2
Suspended	`NCT05064111` - Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
Not yet recruiting	`NCT04031378` - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer	Phase 2
Recruiting	`NCT02600156` - Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors	N/A
Recruiting	`NCT05726292` - A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer	Phase 2
Recruiting	`NCT04423211` - Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	Phase 3
Terminated	`NCT03718338` - Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Terminated	`NCT02564549` - MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca	N/A